What is KAPA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for KAPA?

P/E (TTM) is n/a and 52-week range is $0.85 to $9.59 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s KAPA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for KAPA?

The company profile lists net income (TTM) near $-33M, EPS (TTM) near $-1.53 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Kairos Pharma Ltd based, and what identifiers does Chartloom list?

The company context section lists headquarters in Los Angeles, California, US, 21.4M shares outstanding, ISIN US48301N1046 when available from company profile and filing metadata.

Kairos Pharma Ltd

$KAPA

Health Care · Biotechnology

IR Run Scenarios

$0.81

-15.55%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. The company is headquartered in Los Angeles, California and currently employs 1 full-time employees. The company went IPO on 2024-09-16. The firm is engaged in advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. Its therapy includes antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its portfolio consists of seven drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301 and 401 and therapeutic agents ENV 105 and 205. KROS 101 is a small molecule that targets the glucocorticoid-induced tumor necrosis factor ligand-related (GITR) ligand, a signal for T cell growth to remove a checkpoint barrier to fight a host of cancers. KROS 201 is a T cell therapy activated by dendritic cells to treat glioblastoma, a deadly and common brain cancer. ENV 105 drug seeks to address unmet medical needs in large markets of prostate and lung cancers.

Employees

Website

kairospharma.com

IPO

2024-09-16

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)